{"id":"https://openalex.org/W2761875629","doi":"https://doi.org/10.1093/eurheartj/ehx504.p4019","title":"P4019The impact of age on the effectiveness and safety of the NOACs versus warfarin for stroke prevention in atrial fibrillation","display_name":"P4019The impact of age on the effectiveness and safety of the NOACs versus warfarin for stroke prevention in atrial fibrillation","publication_year":2017,"publication_date":"2017-08-01","ids":{"openalex":"https://openalex.org/W2761875629","doi":"https://doi.org/10.1093/eurheartj/ehx504.p4019","mag":"2761875629"},"language":"en","primary_location":{"id":"doi:10.1093/eurheartj/ehx504.p4019","doi":"https://doi.org/10.1093/eurheartj/ehx504.p4019","is_oa":false,"landing_page_url":"https://doi.org/10.1093/eurheartj/ehx504.p4019","pdf_url":null,"source":{"id":"https://openalex.org/S181568219","display_name":"European Heart Journal","issn_l":"0195-668X","issn":["0195-668X","1522-9645"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Heart Journal","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5043658621","display_name":"Peter A. Noseworthy","orcid":"https://orcid.org/0000-0002-4308-0456","observed_orcids":["https://orcid.org/0000-0002-4308-0456"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"P. Noseworthy","raw_affiliation_strings":["Mayo Clinic, Cardiovascular Diseases, Rochester, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mayo Clinic, Cardiovascular Diseases, Rochester, United States of America","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071976622","display_name":"Xiaoxi Yao","orcid":"https://orcid.org/0000-0001-9906-7106","observed_orcids":["https://orcid.org/0000-0001-9906-7106"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"X. Yao","raw_affiliation_strings":["Mayo Clinic, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Rochester, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mayo Clinic, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Rochester, United States of America","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5041424888","display_name":"Nilay D. Shah","orcid":"https://orcid.org/0000-0002-8597-3447","observed_orcids":["https://orcid.org/0000-0002-8597-3447"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"N.D. Shah","raw_affiliation_strings":["Mayo Clinic, Division of Health Care Policy and Research, Rochester, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mayo Clinic, Division of Health Care Policy and Research, Rochester, United States of America","institution_ids":["https://openalex.org/I1330342723"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I1330342723"],"apc_list":{"value":5240,"currency":"EUR","value_usd":5922},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.23483037,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"38","issue":"suppl_1","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10065","display_name":"Atrial Fibrillation Management and Outcomes","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10065","display_name":"Atrial Fibrillation Management and Outcomes","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10285","display_name":"Venous Thromboembolism Diagnosis and Management","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2724","display_name":"Internal Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10227","display_name":"Acute Ischemic Stroke Management","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/direct-oral-anticoagulants","display_name":"direct oral anticoagulants","score":0.9509999752044678},{"id":"https://openalex.org/keywords/warfarin","display_name":"warfarin","score":0.9570000171661377},{"id":"https://openalex.org/keywords/atrial-fibrillation","display_name":"atrial fibrillation","score":0.9760000109672546},{"id":"https://openalex.org/keywords/stroke-prevention","display_name":"stroke prevention","score":0.9539999961853027},{"id":"https://openalex.org/keywords/age","display_name":"age","score":0.3700000047683716},{"id":"https://openalex.org/keywords/dabigatran","display_name":"dabigatran","score":0.8939999938011169},{"id":"https://openalex.org/keywords/rivaroxaban","display_name":"rivaroxaban","score":1.0},{"id":"https://openalex.org/keywords/apixaban","display_name":"apixaban","score":1.0},{"id":"https://openalex.org/keywords/major-bleeding","display_name":"major bleeding","score":0.9559999704360962},{"id":"https://openalex.org/keywords/stroke-and-systemic-embolism","display_name":"stroke and systemic embolism","score":0.8289999961853027},{"id":"https://openalex.org/keywords/non-valvular-atrial-fibrillation","display_name":"non-valvular atrial fibrillation","score":0.8429999947547913}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9874672889709473},{"id":"https://openalex.org/C2779161974","wikidata":"https://www.wikidata.org/wiki/Q815819","display_name":"Atrial fibrillation","level":2,"score":0.8761510848999023},{"id":"https://openalex.org/C2776301958","wikidata":"https://www.wikidata.org/wiki/Q407431","display_name":"Warfarin","level":3,"score":0.8292072415351868},{"id":"https://openalex.org/C2780645631","wikidata":"https://www.wikidata.org/wiki/Q671554","display_name":"Stroke (engine)","level":2,"score":0.7449831366539001},{"id":"https://openalex.org/C164705383","wikidata":"https://www.wikidata.org/wiki/Q10379","display_name":"Cardiology","level":1,"score":0.4794858396053314},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.42407238483428955},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.3267017602920532},{"id":"https://openalex.org/C127413603","wikidata":"https://www.wikidata.org/wiki/Q11023","display_name":"Engineering","level":0,"score":0.0},{"id":"https://openalex.org/C78519656","wikidata":"https://www.wikidata.org/wiki/Q101333","display_name":"Mechanical engineering","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1093/eurheartj/ehx504.p4019","doi":"https://doi.org/10.1093/eurheartj/ehx504.p4019","is_oa":false,"landing_page_url":"https://doi.org/10.1093/eurheartj/ehx504.p4019","pdf_url":null,"source":{"id":"https://openalex.org/S181568219","display_name":"European Heart Journal","issn_l":"0195-668X","issn":["0195-668X","1522-9645"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Heart Journal","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"score":0.5600000023841858,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3109668938","https://openalex.org/W2762473619","https://openalex.org/W2946158013","https://openalex.org/W3119494248","https://openalex.org/W2981420901","https://openalex.org/W1901011034","https://openalex.org/W2993484809","https://openalex.org/W4205784920","https://openalex.org/W2589092766","https://openalex.org/W4300629690"],"abstract_inverted_index":{"Background:":[0],"Pivotal":[1],"clinical":[2],"trials":[3],"have":[4],"established":[5],"non-vitamin":[6],"K":[7],"antagonist":[8],"oral":[9],"anticoagulants":[10],"(NOACs)":[11],"as":[12],"viable":[13],"alternatives":[14],"to":[15,69,119,126],"warfarin":[16,85,89,94,127],"for":[17,46,141,150,156],"stroke":[18,101,192],"prevention":[19],"in":[20,179,193],"atrial":[21],"fibrillation":[22],"(AF)":[23],"but":[24,174],"age":[25,44,55,131],"may":[26],"be":[27],"an":[28],"important":[29],"determinant":[30],"of":[31,34,54,61,78,122,166,191],"the":[32,52,57,106,123],"risk/benefit":[33],"these":[35],"therapies":[36],"\u2013":[37],"indeed,":[38],"RE-LY":[39],"and":[40,59,64,91,105,129,135,138,152,155,158],"ARISTOTLE":[41],"demonstrated":[42],"potential":[43],"interactions":[45,147],"certain":[47],"endpoints.":[48],"Purpose:":[49],"To":[50],"investigate":[51],"impact":[53],"on":[56],"effectiveness":[58,98],"safety":[60,108],"dabigatran,":[62],"rivaroxaban,":[63],"apixaban,":[65],"comparing":[66],"each":[67,121],"agent":[68],"warfarin.":[70],"Methods:":[71],"We":[72],"created":[73],"three":[74,124],"propensity-score":[75],"matched":[76],"cohorts":[77],"patients":[79,170,180,194],"with":[80,163,188],"nonvalvular":[81],"AF:":[82],"dabigatran":[83,151],"versus":[84,88,93],"(n=34,834),":[86],"rivaroxaban":[87,157],"(n=38,592),":[90],"apixaban":[92],"(n=13,152).":[95],"The":[96],"primary":[97,107],"outcome":[99,109],"was":[100,110,161,186],"or":[102,183],"systemic":[103],"embolism":[104],"major":[111,153,167],"bleeding.":[112],"Cox":[113],"proportional":[114],"hazards":[115],"models":[116],"were":[117,148],"used":[118],"compare":[120],"agents":[125],"overall":[128],"by":[130],"category":[132],"(18\u201364,":[133],"65\u201374":[134],"\u226575":[136],"years)":[137],"we":[139],"tested":[140],"a":[142],"drug-age":[143],"interaction.":[144],"Results:":[145],"Age":[146],"noted":[149],"bleeding":[154,168],"stroke.":[159],"Dabigatran":[160],"associated":[162,187],"lower":[164],"risk":[165,178,190],"among":[169],"under":[171],"75":[172,181],"years,":[173],"trended":[175],"toward":[176],"higher":[177,189],"years":[182],"older.":[184],"Rivaroxaban":[185],"aged":[195],"18\u201364":[196],"years.":[197]},"counts_by_year":[],"updated_date":"2026-09-26T08:19:03.415552","created_date":"2017-10-20T00:00:00"}